Efficacy of Topical Coenzyme Q10 and Curcumin for Oral Leukoplakia Treatment
Clinical and Biochemical Assessment of the Effectivness of Topical Coenzyme Q10 and Topical Curcumin in Managment of Oral Leukoplakia (A Randomized Controlled Clinical Trial)
Alexandria University
34 participants
Nov 25, 2025
INTERVENTIONAL
Conditions
Summary
Oral leukoplakia (OL) is recognized as the most common potentially malignant disorder of the oral mucosa. The pathogenesis of OL is complex and multifactorial, with oxidative stress playing a central role. Topical antioxidants have gained attention as therapeutic options to help stabilize lesions and potentially prevent malignant transformation. Both CoQ10 and curcumin have demonstrated a clinical success as strong antioxidants showing their capacity to reduce the lesion size and to stabilize the disease, ultimately preventing progression into oral malignancy. Aim: This study aims to clinically and biochemically assess the effectiveness of topical Coenzyme Q10 and Curcumin in the management of homogeneous oral leukoplakia.
Eligibility
Inclusion Criteria3
- Clinically and histologically diagnosed with homogeneous oral leukoplakia not indicated for surgical excision .
- Lesions accessible for topical application.
- Willing to sign informed consent and comply with study instructions and return to follow up
Exclusion Criteria7
- Moderate-to-severe dysplasia, carcinoma in situ, or invasive oral cancer.
- Presence of any visible oral lesions except for oral leukoplakia.
- Active periodontal diseases as this can confound salivary biomarkers.
- Significant systemic illness or immunosuppression.
- Patients who have taken systemic or topical antioxidant supplements within the last four weeks will be excluded to avoid confounding effects on salivary biomarkers.
- Pregnant and lactating women will be excluded due to hormonal changes that may alter oxidative stress and ethical considerations.
- Patients unwilling or unable to comply with study requirements.
Interventions
Application will be performed 2-3 times daily for 4 weeks.
Application will be performed 2-3 times daily for 4 weeks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07331935